阿立哌唑与利培酮联合治疗精神分裂症阴性症状的临床疗效及安全性评估

Clinical efficacy of aripiprazole combined with risperidone in the treatment of negative symptoms of schizophrenia and its safety evaluation

目的研究阿立哌唑联合利培酮治疗精神分裂症阴性症状的临床疗效及安全性。方法选择2016年2月—2018年10月本中心收治的精神分裂症患者70例作为研究对象,按照随机数表法分为对照组和观察组两组,每组各35例。对照组单用利培酮治疗,观察组使用阿立哌唑联合利培酮治疗。对比两组治疗4周、8周体重指数(BIM)、糖脂代谢指标、PANSS分值及副反应量表(TESS)。结果治疗8周时对照组BIM显著升高且高于观察组(P<0.05)。治疗4周、8周时观察组TG无显著变化(P>0.05);对照组TG升高且高于观察组(P<0.05);两组FBG、TC并无显著变化,组间比较也无统计学差异(P>0.05)。治疗4周及8周时两组阴性症状分值均降低,且观察组低于对照组(P<0.05);治疗8周时两组患者PANSS总分均降低,且低于对照组(P<0.05)。观察组不良反应发生率为20.00%,对照组为48.57%,组间差异具有统计学意义(P<0.01),观察组TESS分值为(3.01±0.91)分,低于对照组的(3.65±1.01)分,组间差异具有统计学意义(P<0.05)。结论阿立哌唑联合利培酮治疗精神分裂症阴性症状的疗效优于单用利培酮治疗,且不良反应少,安全性高。

Objective To study the efficacy and safety of aripiprazole combined with risperidone in the treatment of negative symptoms of schizophrenia.Methods Seventy patients with schizophrenia those admitted to Heyuan mental health center from February 2016 to October 2018 were enrolled in the study. They were randomly divided into two groups according to the random number table, 35 cases in each group. The control group was treated with risperidone alone, while the observation group was treated with aripiprazole combined with risperidone. Body mass index(BMI), glucose and lipid metabolism index, PANSS score and scores of side effect scale(TESS) were compared between the two groups at 4 th and 8 th week of treatment.Results After 8 weeks of treatment, BMI in the control group increased significantly and was higher than that in the observation group(P<0.05). TG in the observation group showed no significant change after 4 and 8 weeks of treatment(P>0.05). TG in the control group was higher than that in the observation group(P<0.05). There was no significant change in FBG and TC between the two groups, and there was no statistical difference between the two groups(P>0.05). At 4 weeks and 8 weeks of treatment, the negative symptom scores of both groups were decreased, and the observation group was lower than the control group. After 8 weeks of treatment, the total PANSS scores of both groups were decreased, and that of observation group was lower than the control group(P<0.05). The incidence of adverse reactions was 20.00% in the observation group and 48.57% in the control group, and the score of TESS in the observation group(3.01±0.91) was lower than that in the control group(3.65±1.01)(P<0.01).Conclusions The efficacy of aripiprazole combined with risperidone in the treatment of negative symptoms of schizophrenia was better than risperidone alone, meanwhile it inducing less adverse reactions with high safety level.